Generex Biotechnology Corp (GNBT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Generex Biotechnology Corp (GNBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12409
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.

Generex Biotechnology Corp (GNBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Antigen Express Enters into Agreement with Merck for KEYTRUDA 11
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 12
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 13
Licensing Agreements 14
Antigen Express Enters into Licensing Agreement with Shenzhen BioScien Pharma 14
Equity Offering 15
Generex Biotech Raises USD3 Million in First Tranche of Private Placement of Shares 15
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Acquisition 20
Generex Biotech to Acquire 51% Stake in Regentys 20
Generex Biotech to Acquire 51% Stake in Emmaus Life Sciences for USD225 Million 21
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 23
Generex Biotechnology Corp – Key Competitors 24
Generex Biotechnology Corp – Key Employees 25
Generex Biotechnology Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Corporate Communications 27
Nov 15, 2018: Generex announces appointment of executive management team 27
Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 29
Jun 25, 2018: Generex Names Terry Thompson As Chief Operating Officer 30
Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology 31
Other Significant Developments 32
Jan 04, 2018: Generex CEO Provides 2017 Year-End Summary to Stakeholders 32
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Antigen Express Enters into Agreement with Merck for KEYTRUDA 11
Generex Biotech Enters into Licensing Agreement with CannScience Innovations 12
Generex Biotech to Enter into Co-Development Agreement with NHTherapeutics 13
Antigen Express Enters into Licensing Agreement with Shenzhen BioScien Pharma 14
Generex Biotech Raises USD3 Million in First Tranche of Private Placement of Shares 15
Generex Biotechnology Raises USD0.8 Million in Private Placement of Series E 9% Convertible Preferred Stock and Warrants 17
Generex Biotech Completes Private Placement Of Units For US$2 Million 18
Generex Biotech to Acquire 51% Stake in Regentys 20
Generex Biotech to Acquire 51% Stake in Emmaus Life Sciences for USD225 Million 21
Generex Biotech to Acquire 51% Stake in Alfa Rhythm for USD5 Million 23
Generex Biotechnology Corp, Key Competitors 24
Generex Biotechnology Corp, Key Employees 25
Generex Biotechnology Corp, Subsidiaries 26

List of Figures
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Generex Biotechnology Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Generex Biotechnology Corp (GNBT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SBI Biotech Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary SBI Biotech Co Ltd (SBI), a subsidiary of SBI Holdings Inc, is a developer of molecule targeting drugs and immune modulation drugs. The company develops DNA nucleotide drugs targeting TLR and antibody drugs targeting dendritic cells. Its pipeline products include ILT7, SBI-9674, SBI-3150, GN …
  • Foxconn Technology Co Ltd:企業のM&A・事業提携・投資動向
    Foxconn Technology Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Foxconn Technology Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Kkr Financial Holdings Llc:企業の戦略・SWOT・財務分析
    Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report Summary Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Fred Hutchinson Cancer Research Center:企業のM&A・事業提携・投資動向
    Fred Hutchinson Cancer Research Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fred Hutchinson Cancer Research Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Eidgenossische Technische Hochschule Zurich:製薬・医療:M&Aディール及び事業提携情報
    Summary Eidgenossische Technische Hochschule Zurich (ETH Zurich) is an educational service provider that offers studies in technology and the natural sciences. The university offers scientific education through bachelor programmes and master programmes in the areas of applied geophysics, architectur …
  • Renata Ltd (RENATA):企業の財務・戦略的SWOT分析
    Summary Renata Ltd (Renata), formerly Pfizer Ltd, is a pharmaceutical and animal health product company. The company manufactures generic pharmaceutical products including hormones, contraceptives, anti cancer drugs, oral preparations, and other drugs. Its pharmaceutical product portfolio comprises …
  • Centene Corp (CNC):企業の財務・戦略的SWOT分析
    Centene Corp (CNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Virgin Atlantic Airways Ltd:企業の戦略・SWOT・財務情報
    Virgin Atlantic Airways Ltd - Strategy, SWOT and Corporate Finance Report Summary Virgin Atlantic Airways Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Barton Malow Co:企業の戦略的SWOT分析
    Barton Malow Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • China Non-ferrous Metal Industry’s Foreign Engineering and Construction Co Ltd:企業の戦略・SWOT・財務分析
    China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Qaf Limited
    Qaf Limited - Strategy, SWOT and Corporate Finance Report Summary Qaf Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Synthetic Genomics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Synthetic Genomics Inc (Synthetic Genomics) is a provider of synthetic biology and synthetic genomics solutions. The company provides DNA synthesis services, instrumentation, reagents, and bioinformatics services and software packages, among others. It provides solutions in genomics research …
  • Qiagen NV (QIA):医療機器:M&Aディール及び事業提携情報
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • Gentag Inc-医療機器分野:企業M&A・提携分析
    Summary Gentag Inc (Gentag) is a medical device company that patent and develops wireless sensor technology products. The company provides wireless products to personal health and diagnostics. It offers wireless sensor network services. Gentag’s products comprise medication and packaging sensor, imm …
  • Hosken Consolidated Investments Ltd (HCI):企業の財務・戦略的SWOT分析
    Hosken Consolidated Investments Ltd (HCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析
    Summary Strongbridge Biopharma plc (Strongbridge), formerly Cortendo plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokale …
  • Mosman Oil & Gas Ltd (MSMN):石油・ガス:M&Aディール及び事業提携情報
    Summary Mosman Oil & Gas Ltd (MOG) is an oil and gas company. The company operates in the exploration, development, and production of oil and gas projects. Its projects include amadeus basin, welch permian basin, blackstone strategic alliance, strawn oil project, and arkoma stacked pay project. MOG’ …
  • Britvic Plc:企業の戦略・SWOT・財務情報
    Britvic Plc - Strategy, SWOT and Corporate Finance Report Summary Britvic Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TVA Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary TVA Medical Inc (TVA Medical) is a medical device company that designs and manufactures catheter-based systems. The company offers minimally invasive therapies for treatment of end stage renal disease. It offers everlinq, an endovascular device used for creating an AV fistula for hemodialysi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆